• Title/Summary/Keyword: vaccine safety

Search Result 179, Processing Time 0.028 seconds

Comparison of Factors Associated with Intention to Receive Human Papillomavirus Vaccine Between Male and Female Undergraduate Students (남녀 대학생의 인유두종 바이러스 백신접종의도 영향요인 비교)

  • Kim, Hae-Won
    • Women's Health Nursing
    • /
    • v.17 no.4
    • /
    • pp.415-425
    • /
    • 2011
  • Purpose: This study was done to identify and compare factors associated with intention to receive Human Papillomavirus (HPV) vaccine between male and female undergraduate students. Methods: In the fall of 2010, 479 students responded to self-administered questionnaires about their intention to receive HPV vaccine, HPV knowledges, HPV related involvements and optimistic bias, subject's characteristics including opinion about HPV vaccine. Mann-Whitney U test, uni-variate and multi-variate logistic regression were used for data analysis with SPSS/WIN. Results: Intention to receive vaccine were 22.0% of men and 25.0% of women. There were significantly different in HPV knowledge (Z=-2.74, p=.006), optimistic bias (Z=-4.60, p<.001), vaccine is necessary for women (Z=-4,30, p<.001), vaccine is necessary for men (Z=-4.37, p<.001), vaccine is necessary if only symptom exist (Z=-4.52, p<.001), but there were not different in intention to receive vaccine, involvement between men and women. Concern about vaccine safety (OR=3.19, 95% CI 1.63~6.23) was determinant of intention to receive HPV vaccine for men. Conclusion: This study showed gender differences in HPV knowledge, HPV related optimistic bias and opinion about HPV vaccine, which would be assessed and well managed in tailored HPV education for enhancing HPV vaccine acceptance.

Perspectives of AIDS Vaccine Development: T Cell-based Vaccine

  • Sung, Young Chul
    • IMMUNE NETWORK
    • /
    • v.2 no.1
    • /
    • pp.1-5
    • /
    • 2002
  • Estimated number of adults and children newly infected with HIV-1 during 2001 alone is 5 million in total. An effective vaccine, in addition to education & public health approaches, has been believed to be the best option to stop the HIV-1 transmission, especially for developing countries. Among AIDS vaccine candidates, DNA vaccine is relatively safe and, in a certain extent, mimics some attributes of live attenuated vaccine, with regard to in vivo gene expression & the type of immunity induced. We recently demonstrated that DNA vaccines expressing SIVmac239 structural and regulatory genes, augmented with coadministration of IL-12 mutant induced the strongest T cell responses, resulting in low to undetectable setpoint viral loads, stable $CD4^+$ T cell counts, and no evidence of clinical diseases or mortality by day 420 after challenge. This finding is the second demonstration, following the protective result of live attenuated SIV vaccine in SIVmac-rhesus monkey model, which was known to have safety problem. So, our DNA vaccines could give a significant impact on HIV-1 epidemic by slowing or stopping the spread of HIV-1, leading to eventual eradication of HIV-1 and AIDS in the population.

A Real-Time Surveillance System for Vaccine Cold Chain Based o n Internet of Things Technology

  • Shao-jun Jiang;Zhi-lai Zhang;Wen-yan Song
    • Journal of Information Processing Systems
    • /
    • v.19 no.3
    • /
    • pp.394-406
    • /
    • 2023
  • In this study, a real-time surveillance system using Internet of Things technology is proposed for vaccine cold chains. This system fully visualizes vaccine transport and storage. It comprises a 4G gateway module, lowpower and low-cost wireless temperature and humidity collection module (WTHCM), cloud service software platform, and phone app. The WTHCM is installed in freezers or truck-mounted cold chain cabinets to collect the temperature and humidity information of the vaccine storage environment. It then transmits the collected data to a gateway module in the radiofrequency_physical layer (RF_PHY). The RF_PHY is an interface for calling the bottom 2.4-GHz transceiver, which can realize a more flexible communication mode. The gateway module can simultaneously receive data from multiple acquisition terminals, process the received data depending on the protocol, and transmit the collated data to the cloud server platform via 4G or Wi-Fi. The cloud server platform primarily provides data storage, chart views, short-message warnings, and other functions. The phone app is designed to help users view and print temperature and humidity data concerning the transportation and storage of vaccines anytime and anywhere. Thus, this system provides a new vaccine management model for ensuring the safety and reliability of vaccines to a greater extent.

An Outer Membrane Protein Preparation as a Vaccine against Pseudomonas aeruginosa Infection

  • Park, Wan-Je;Cho, Yang-Je;Ahn, Dong-Ho;Jung, Sang-Bo;Lee, Na-Gyong;Kim, Hyun-Su;Hahm, Kyung-Soo;Kim, Yu-Sam
    • Journal of Microbiology and Biotechnology
    • /
    • v.7 no.2
    • /
    • pp.144-150
    • /
    • 1997
  • We developed a simple and efficient method to prepare a Pseudomonas vaccine of outer membrane (OM) proteins free from lipopolysaccharide (LPS). A three step purification process including extraction, ultrafiltration and ultracentrifugation effectively removed LPS from the OM protein fraction. Approximately 2 mg of the OM proteins was obtained from 1 g of wet cell. LPS contaminant in the vaccine preparation was less than 0.003% (w/w) of protein and protease activity was not detectable. To achieve a wide range of protection, OM proteins prepared from four attenuated P. aeruginosa strains were mixed in equal amounts and used as a vaccine, which elicited in rabbits a high titer of antibody reactive to all of the seven Fisher types. The antisera from the immunized rabbit had a strong reactivity to vaccine proteins larger than 25 kDa. In a burned mouse infection model, immunization with the vaccine significantly enhanced bacterial clearance in the Pseudomonas infected skin. The vaccination also provided mice an excellent protection against Pseudomonas infection (11, 16). Data on antigenicity, mutagenicity, acute, subacute toxicity and pharmacological tests confirmed the safety of the vaccine (1, 3, 10, 12, 17). These data demonstrate that this method can be applied to manufacture a bacterial vaccine of OM proteins with safety and prophylactic efficacy at a practical low cost.

  • PDF

Safety and Immunogenicity of Salmonella enterica Serovar Typhimurium llaB in Mice

  • CHO SUN-A;LEE IN-SOO;PARK JONG-HWAN;SEOK SEUNG-HYEOK;LEE HUI-YOUNG;KIM DONG-JAE;BACK MIN-WON;LEE SEOK-HO;HUR SOOK-JIN;BAN SANG-JA;LEE YOO-KYOUNG;PARK JAE-HAK
    • Journal of Microbiology and Biotechnology
    • /
    • v.15 no.3
    • /
    • pp.609-615
    • /
    • 2005
  • The safety and immunogenicity of an attenuated recombinant Salmonella vaccine strain, Salmonella enterica serovar Typhimurium llaB, was assessed. This vaccine strain could survive in low pH condition, and its ability of intracellular survival did not differ from that of S. enterica serovar Typhimurium UK1, which is the wild-type of the vaccine strain. The mortality of the mice orally administered with the vaccine strain was $50\%$ at the dose of $10^7$ CFU. All mice administered with $10^5\;or\;10^3$ CFU of the vaccine strain survived for 3 days postinoculation (pi). However, all mice administered with more than $10^3$ CFU of the vaccine strain died within 3 days pi. To examine the protective effect of the vaccine strain, mice were orally immunized with $10^4\;and\;10^6$ CFU of the bacteria. Control mice were given with 0.5 ml of phosphate buffered saline (PBS). After 8 days, the mice were challenged with $10^9$ CFU of S. enterica serovar Typhimurium UK1, and mortality was examined for 5 days. The survival rates of the mice immunized with $10^4\;and\;10^6$ CFU of the vaccine strain were $60\%\;and\;80\%$, respectively, whereas all control mice died within 2 days after challenging. To investigate the immunogenicity of S. enterica serovar Typhimurium llaB, mice were orally immunized with $10^5\;or\;10^6$ CFU ml of the vaccine strain. Five mice of each group were sacrificed at 5 and 12 days after immunization, and results showed that immunization of the vaccine strain led to increases of IgG1, IgG2, and IgM titers against S. enterica serovar Typhimurium UK1 in mouse sera, cytokine expressions such as IL-2, IL-4, IL-6, and IL-10 in spleen, and the lymphocyte proliferation response to mitogens (concanavalin A or LPS) stimulation.

Need for a safe vaccine against respiratory syncytial virus infection

  • Kim, Joo-Young;Chang, Jun
    • Clinical and Experimental Pediatrics
    • /
    • v.55 no.9
    • /
    • pp.309-315
    • /
    • 2012
  • Human respiratory syncytial virus (HRSV) is a major cause of severe respiratory tract illnesses in infants and young children worldwide. Despite its importance as a respiratory pathogen, there is currently no licensed vaccine for HRSV. Following failure of the initial trial of formalin-inactivated virus particle vaccine, continuous efforts have been made for the development of safe and efficacious vaccines against HRSV. However, several obstacles persist that delay the development of HRSV vaccine, such as the immature immune system of newborn infants and the possible Th2-biased immune responses leading to subsequent vaccine-enhanced diseases. Many HRSV vaccine strategies are currently being developed and evaluated, including live-attenuated viruses, subunit-based, and vector-based candidates. In this review, the current HRSV vaccines are overviewed and the safety issues regarding asthma and vaccine-induced pathology are discussed.

Evaluation of systemic and mucosal immune responses in mice administered with recombinant Salmonella Typhimurium expressing IutA protein

  • Oh, In-Gyeong;Choi, Minsu;Lee, John Hwa
    • Korean Journal of Veterinary Research
    • /
    • v.53 no.3
    • /
    • pp.163-167
    • /
    • 2013
  • Avian pathogenic Escherichia coli (APEC) are known to cause extraintestinal disease in poultry, leading to substantial losses in the industry. IutA, iron-regulated aerobactin receptor is firmly associated with APEC. To assess the potential of IutA to induce protective immune responses, attenuated Salmonella Typhimurium strain expressing IutA was constructed and administered orally to BALB/c mice. The IutA-specific immune responses were measured with sera, vaginal and fecal samples by an enzyme-linked immunosorbent assay. We found that the Salmonella-IutA vaccine induced significantly higher immune responses as compared to the control inoculated with the attenuated S. Typhimurium containing the plasmid only. The IutA-specific immune responses were increased by second immunization at third week after initial immunization, whereas triple immunization induced lower immune responses than those induced by the double immunization. The Salmonella-IutA vaccine induced a nature of immunity biased to the Th1-type, as judged by the ratio of IutA-specific IgG isotypes (IgG2a/IgG1). Overall, these results suggest that the Salmonella-IutA vaccine appear to be suitable candidate for a vaccine against APEC.

A Delphi Study on National Public Vaccine Research and Development Policy in Korea (델파이기법을 활용한 국가 공공(公共)백신 연구개발 정책수립 기초조사)

  • Lee, Somin;Yeo, Sang-Gu;Kang, Shin Jung;Han, Soon Young;Lee, Sang-Won
    • Health Policy and Management
    • /
    • v.25 no.2
    • /
    • pp.140-148
    • /
    • 2015
  • Vaccination is the most powerful and useful preparation against infectious diseases. However, developing vaccines costs a lot and requires extensive long-term efforts. Therefore, the government should research and develop vaccines with a national-level policy. To greatly enhance the success rate of vaccine development, the policy should be set up considering priorities such as the current status of domestic research, the importance for public health, the urgency of research. The Delphi technique was utilized to draft this survey, through a brainstorming stage, then two inquiries, and finally the final panel meeting where unresolved items were discussed, to draw the conclusion. Among the results, firstly, the highest ranked item on centralized fields for vaccine development by the Ministry of Health was 'self-sufficiency of vaccines.' Secondly, 'emerging infectious disease' was most highly ranked in prioritized fields of vaccine development and research. Thirdly, for the vaccine that needs to be improved and developed further by the government to improve its efficacy and safety, BCG (Bacille de Calmette) for tuberculosis was ranked the highest on both types (intradermal and subcutaneous injection) from National Immunization Programme (NIP) and non-NIP. As for the high risk pathogens, 'anthrax' and 'smallpox' were first and second, consecutively. Lastly, 'development and control of vaccine candidates' was ranked the highest for the area in need for technique development in order to improve domestic vaccine's research level. The results of this study will be put to good use as basic data for the national vaccine research and development (R&D) policy of the country. This study was first step and more studies should be carried out for the final decision of the national vaccine R&D priority.

Post-marketing Surveillance Study of an Inactivated Split-Virion Influenza Vaccine in Korea (불활화 분할 인플루엔자 백신의 국내 시판 후 조사 연구)

  • Huh, Jae-Won;Ma, Sang-Hyuk;Kim, Hyun-Kyun;Gunapalaiah, Bhavyashree;Bock, Hans L.;on behalf of the Fluarix-054 Study Group,
    • Pediatric Infection and Vaccine
    • /
    • v.18 no.1
    • /
    • pp.68-79
    • /
    • 2011
  • Purpose : This post-marketing surveillance study (NCT00750360) assessed the safety and reactogenicity of an inactivated, trivalent split-virion influenza vaccine licensed for use in the Korea since 2002. Methods : Eight hundred and eighty three subjects aged 6 months received a single dose of the ${\geq}$ vaccine; an additional dose was administered to those aged <9 years and unprimed with an influenza vaccine. Four hundred and eleven subjects used diary cards to record safety information; this report presents data from these subjects. Incidence of solicited local, general and unsolicited adverse events (4-days and 21-days post-vaccination follow-up periods, respectively) were recorded. Serious adverse events (SAEs) were recorded throughout the study period. Results : Injection site pain (subjects aged <6 years: 12.6% of subjects, ${\geq}$6 years: 34.7%), fever (<6 years: 1.3%) and myalgia (${\geq}$6 years: 13.9%) were the most frequently recorded solicited local and general adverse events. Grade 3 solicited adverse events were reported by ${\leq}$4.0% subjects. No vaccine-related SAEs were recorded (KFDA criteria). Conclusion : Considering the vaccine's well-established immunogenicity and its favourable safety and reactogenicity profile across all age groups and its high coverage rate in Korea, it may be recommended as a candidate to facilitate annual seasonal influenza vaccination for all ages as part of the Korean National Immunization Program.

Recombinant zoster vaccine (Shingrix®): a new option for the prevention of herpes zoster and postherpetic neuralgia

  • Singh, Grisuna;Song, Sejin;Choi, Eunjoo;Lee, Pyung-Bok;Nahm, Francis Sahngun
    • The Korean Journal of Pain
    • /
    • v.33 no.3
    • /
    • pp.201-207
    • /
    • 2020
  • Postherpetic neuralgia (PHN) is a challenging condition for pain management specialists. The prevention of herpes zoster (HZ) and subsequent PHN in individuals aged 50 years and older, via the development of new vaccines, is an ongoing research project. The live zoster vaccine (LZV, Zostavax®) was the first proof of concept that vaccination could prevent HZ, but LZV cannot be used in various immunecompromised patients. This led to the development of a new non-live recombinant zoster vaccine (RZV, Shingrix®). This RZV has shown promising results in many clinical trials, with high reactogenicity and similar systemic adverse effects compared to those of LZV. The National Advisory Committee on Immunization has recommended LZV as a standard vaccine for HZ prevention in adults ≥ 50 years of age, but no studies directly comparing the safety and efficacy of RZV and LZV vaccines have been conducted. This article reviews the brief history, efficacy, and safety of the two vaccines and discusses the advantage of RZV over LZV based on the available literature.